In vitro stability of insulin lispro in continuous subcutaneous insulin infusion

Diabetes Technology and Therapeutics

Volumn 8, Issue 3, 2006, Pages 358-368

  DeFelippis, Michael R ^a   Bell, Maureen A ^a   Heyob, Jennifer A ^a   Storms, Sacha M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LISPRO; META CRESOL; 4-CRESOL; ANTIDIABETIC AGENT; CRESOL; DRUG DERIVATIVE; INSULIN; PARA CRESOL;

ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FORMULATION; EXERCISE TEST; HIGH TEMPERATURE; HUMAN; IN VITRO STUDY; INSULIN INFUSION; MICROBIAL CONTAMINATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; VISCOSITY; BLOOD; CHEMISTRY; DRUG STABILITY; INSULIN DEPENDENT DIABETES MELLITUS; SKIN; VASCULARIZATION;

CRESOLS; DIABETES MELLITUS, TYPE 1; DRUG STABILITY; EXERCISE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; SKIN;

EID: 33748427396     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.8.358     Document Type: Article

References (30)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996;45:1289-1298.
3. Robertson KE, Glazer NB, Campbell RK: The latest developments in insulin injection devices. Diabetes Educ 2000;26:135-152.
4. DeFelippis MR, Chance RE, Frank BH: Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst 2001;18:201-264.
5. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-443.
6. Renner R, Pfützer A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999;22:784-788.
7. Hanaire-Broutin H, Melki V, Bressières-Lacombe S, Tauber J-P: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 2000;23:1232-1235.
8. Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F: A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 2001;15:295-300.
9. Bode BW, Strange P: Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
10. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang W-C, Reinhardt RR: Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002;25:439-444.
11. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003;26:2598-2603.
12. Brange J, Langkjær L, Havelund S, Vølund A: Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res 1992;9:715-726.
13. Brange J, Havelund S, Hougaard P: Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res 1992;9:727-734.
14. Sefton MV, Antonacci GM: Adsorption isotherms of insulin onto various materials. Diabetes 1984;33:674-680.
15. Brange J, Havelund S: Insulin pumps and insulin quality-requirements and problems. Acta Med Scand Suppl 1983;671:135-138.
16. Feingold V, Jenkins AB, Kraegen EW: Effect of contact material on vibration-induced insulin aggregation. Diabetologia 1984;27:373-378.
17. Hutchison KG: Assessment of gelling in insulin solutions for infusion pumps. J Pharm Pharmacol 1985;37:528-531.
18. Sluzky V, Tamada JA, Klibanov AM, Langer R: Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci USA 1991;88:9377-9381.
19. Demirdjian S, Bardin C, Savin S, Zirinis P, Chast F, Slama G, Selam J-L: Lispro insulin is suitable for external pumps but not for implantable pumps. Diabetes Care 1998;21:867-868.
20. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM, Frank BH: Stability of insulin lispro in insulin infusion systems. Diabetes Care 1997;20:1061-1065.
21. U.S. Food and Drug Administration Draft Guidance: Requirements Proposed for Pump Insulins and Insulin Pumps. Rockville, MD: U.S. Food and Drug Administration, 1985.
22. U.S. Pharmacopeia General Chapters: (791) pH. In: USP29-NF24. Rockville, MD: U.S. Pharmacopeial Convention, 2005:2730-2731.
23. U.S. Pharmacopeia Monographs: Insulin Lispro Injection. In: USP29-NF24. Rockville, MD: U.S. Pharmacopeial Convention, 2005:1137-1138.
24. U.S. Pharmacopeia General Chapters: (51) Antimicrobial Effectiveness Testing. In: USP29-NF24. Rockville, MD: U.S. Pharmacopeial Convention, 2005:2499-2500.
25. Brange J, Langkjær L: Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. Acta Pharm Nord 1992;4:149-158.
26. Brange J: Chemical stability of insulin. 4. Mechanisms and kinetics of chemical transformations in pharmaceutical formulation. Acta Pharm Nord 1992;4:209-222.
27. Brange J, Hallund O, Sørensen E: Chemical stability of insulin. 5. Isolation, characterization and identification of insulin transformation products. Acta Pharm Nord 1992;4:223-232.
28. Chantelau E, Lange G, Gasthaus M, Boxberger M, Berger M: Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy. Diabetes Care 1987;10:348-351.
29. Tarr BR, Campbell RK, Workman TM: Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days. Am J Hosp Pharm 1991;48:2631-2634.
30. Poulsen C, Langkjær L, Worsøe C: Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther 2005;7:142-150.